SLC2A1
MOLECULAR TARGETsolute carrier family 2 member 1
SLC2A1 (solute carrier family 2 member 1) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting SLC2A1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gossypol | 4.42 | 82 |
| 2 | phloretin | 3.71 | 40 |
| 3 | colforsin | 3.53 | 33 |
| 4 | cytochalasin b | 3.09 | 21 |
| 5 | bay 876 | 1.95 | 6 |
| 6 | Genistein | 1.39 | 3 |
| 7 | Resveratrol | 1.10 | 2 |
| 8 | Glucose | 1.10 | 2 |
| 9 | Kaempferols | 0.69 | 1 |
| 10 | Anisomycin | 0.69 | 1 |
| 11 | cycloheximide | 0.69 | 1 |
| 12 | Emetine | 0.69 | 1 |
About SLC2A1 as a Drug Target
SLC2A1 (solute carrier family 2 member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented SLC2A1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
SLC2A1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.